Stay updated on ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial
Sign up to get notified when there's something new on the ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial page.

Latest updates to the ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe ClinicalTrials.gov record for the ROSCO-CF roscovitine study is displayed with its study details, participant criteria, locations, outcome measures, investigators, and publication information. The record indicates that the study was terminated and is no longer recruiting participants.SummaryDifference57%

- Check19 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.3%

- Check26 days agoChange DetectedA notice about NIH website updates and the transition from “Artificial Intelligence” to “Super Intelligence” appears above the ClinicalTrials.gov error page.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content. The detailed ROSCO-CF study information and metadata are removed from view.SummaryDifference19%

Stay in the know with updates to ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial page.